Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis.
Kyritsis
Athanassios P
AP
Tachmazoglou
Fanny
F
Rao
Jasti S
JS
Puduvalli
Vinay K
VK
D017209:Apoptosis; D001254:Astrocytoma / Q000188:drug therapy* / Q000378:metabolism; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*
D001897:Boronic Acids; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines; D053221:TNF-Related Apoptosis-Inducing Ligand; D000069286:Bortezomib